Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.

ABSTRACT: Beyond the encouraging results and broad clinical applicability of immune checkpoint (ICP) inhibitors in cancer therapy, ICP-based immunotherapies in the context of autoimmune disease, particularly multiple sclerosis (MS), have garnered considerable attention and hold great potential for developing effective therapeutic strategies. Given the well-established immunoregulatory role of ICPs in maintaining a balance between stimulatory and inhibitory signaling pathways to promote immune tolerance to self-antigens, a dysregulated expression pattern of ICPs has been observed in a significant proportion of patients with MS and its animal model called experimental autoimmune encephalomyelitis (EAE), which is associated with autoreactivity towards myelin and neurodegeneration. Consequently, there i

SUBMITTER: Daei Sorkhabi A 

PROVIDER: S-EPMC10634124 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature